Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial

Keyphrases

• Body Mass Index 8%
• Clinical Vertebral Fracture 41%
• Coronary Artery Disease 16%
• Coronary Events 8%
• Family History 8%
• Femur 8%
• Fracture History 8%
• Fracture Risk 100%
• Hazard Ratio 33%
• High Risk 16%
• Hip Fracture 8%
• Hormone Therapy 8%
• Hormone Use 8%
• Low BMD 8%
• Low Risk 16%
• Medical Records 8%
• Nonvertebral 16%
• Nonvertebral Fracture 33%
• Older Women 8%
• Osteoporosis 16%
• Physical Activity Level 8%
• Placebo 8%
• Placebo Groups 8%
• Postmenopausal Women 100%
• Raloxifene 100%
• Randomized Placebo-controlled Trial 8%
• Risk Category 8%
• Risk Factors 25%
• Risk Score 8%
• Risk Treatment 8%
• Semiannual 8%
• Smoking Status 8%
• Statin Use 8%
• Thyroid Hormones 8%
• Treatment Effect 8%
• Type 1 Diabetes Mellitus (T1DM) 8%
• Weight Loss 8%
• Wrist 8%
• X-ray 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetes Mellitus 8%
• Endocrine Therapy 8%
• Hip Fracture 8%
• Ischemic Heart Disease 16%
• Placebo 25%
• Raloxifene 100%
• Spine Fracture 41%
• Statin (Protein) 8%
• Thyroid Hormone 8%